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ABSTRACT-With the passing of Dr Robert Bittman from pancreatic cancer on the 1st 
October 2014, the lipid research field lost one of the most influential and significant 
personalities.  Robert %LWWPDQ¶Vgenius was in chemical design and his contribution to the 
lipid research field was truly immense.  The reagents and chemicals he designed and 
synthesised allowed interrogation of the role of lipids in constituting complex biophysical 
membranes, sterol transfer and in cellular communication networks.  Here we provide a 
review of these works which serve as a lasting memory to his life. 
 
Introduction 
Robert Bittman (Fig. 1) published 340 peer-reviewed papers, contributed 64 book chapters and 
filed 19 US patents.  He was funded continuously by the National Institute of Health from 1973 
to the beginning of 2014 and he was awarded distinguished MERIT funding from the National 
Heart Lung and Blood Institute from 1986.  International recognition included him receiving 
The Avanti Award of the American Society of Biochemistry and Molecular Biology in 2003 
and a Fellowship from the American Association for the Advancement of Science in 2004.   
For WKHSXUSRVHRIWKLVUHYLHZZHKDYHIRFXVHGRQ%LWWPDQ¶VFRQWULEXWLRQWRXQGHUVWDQGLQJ
lipid trafficking and the role of sphingolipids (e.g. ceramide, sphingosine and sphingosine 1-
phosphate (S1P), ceramide 1-phosphate (C1P)) and phospholipids (e.g. lysophosphatidic acid 
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(LPA), ether glycerol lipids) in cellular communication networks governing cancer biology, 
inflammation and other diseases.  We treat these works in a reflective manner to provide some 
measure of their impact on the key issues that were facing the field at the time.  Indeed, 
%LWWPDQ¶VUHVHDUFKKDVLQIOXHQFHGDOOWKHPDMRUDUHDVFRQFHUQLQJWKHVHELRDFWLYHOLSLGVDQGRQH
would hope that his work might ultimately influence the development of therapeutics in the 
future that will tackle the terrible disease that took his life. 
 
Lipid trafficking 
Bittman published extensively on sterol biochemistry.  Examples include the assessment of the 
distribution of cholesterol between the outer and inner halves of the lipid bilayer of 
mycoplasma cell membranes [1].  He also determined the rates of rapidly exchanging 
cholesterol and phospholipid pools in sphingomyelin- and phosphatidylcholine-containing 
membranes [2].  Bittman also investigated how sphingomyelin modulates trans-bilayer 
distribution of galactosylceramide in phospholipid containing membranes [3].  Using 
fluorescence quenching assays, he established a role for ceramide in lipid raft organisation and 
as a determinant of sterol content [4].  Bittman also synthesised BODIPY (boron-
dipyrromethene)-cholesterol, which was then used to visualise sterol trafficking in cells [5]. The 
egress of BODIPY cholesterol (BC) from late endosomal (LE) organelles is dependent on acid 
lipase and Niemann-Pick C1 (NPC1) protein [6]. NPC1 was shown to recruit Rab8a to BC-
containing LEs and to thereby enhance the motility and segregation of BC- and CD63-positive 
organelles from lysosomes. Low density lipoprotein (LDL) increased the number and dynamics 
of focal adhesions and stimulated cell migration in an acid lipase-, NPC1- and Rab8a-
dependent manner. Further advances include the demonstration that N-myc downstream-
regulated gene 1 (NDRG1) regulates LDL uptake by LDL receptor [7].   
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Bittman and colleagues also demonstrated that the Sonic Hedgehog receptor, Patched might 
contribute to cholesterol efflux from cells, thereby affecting intracellular cholesterol 
concentration [8]. This activity likely accounts for the inhibition of sonic hedgehog signalling 
receptor, Smoothened, enrichment at the plasma membrane [8] and which is an important step 
in activation of the sonic hedgehog signalling pathway.  Sonic hedgehog signalling has a 
critical function in regulating growth and patterning during embryonic development, and also 
in stem cell maintenance and tissue regeneration in adults.   
 
Bittman and Ikonen used sphingomyelin, ceramide and sphingosine labelled with [3H] in 
carbon-3 of the sphingosine backbone and targeted them to the late endosomes and lysosomal 
compartment (LE/LY) in low-density lipoprotein (LDL) particles. These probes were routed 
through the LE/LY sphingolipid degradation and recycling pathway.  They demonstrated that 
NPC1 does not play a significant role in LE/LY sphingosine export.  Instead, NPC1-deficient 
cells displayed an increased affinity for sphingosine independently of protein-mediated lipid 
transport [9].  Bittman and Pagano and colleagues also demonstrated that the endocytosis of 
fluorescent glycosphingolipid (GSL) analogues occurs via a caveolar-dependent mechanism 
[10].  Collaboration with Wilschut and colleagues demonstrated that the alphavirus Semliki 
Forest virus (SFV) enters cells through receptor-mediated endocytosis that involves 
stereospecific interaction of the viral fusion protein with D-erythro sphingolipids in the target 
membrane [11].  These studies collectively advanced the lipid trafficking field made possible 
by ingenious synthesis of highly specific lipid tools. 
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Sphingolipid Signalling 
,Q WKH PLG ¶V WKH FRQFHSW RI WKH sphingolipid rheostat was proposed, where inter-
conversion of ceramide, sphingosine and S1P by various enzymes was suggested to regulate 
cellular fate.  In this model, shifting the balance toward ceramide induces apoptosis, while 
predominance of S1P formation promotes cell survival. However, the sphingolipid rheostat 
exhibits complexity and has recently been re-evaluated [12], as there is temporal and spatial 
regulation, where functionality is governed by compartmentalised signalling [13].  A measure 
of this complexity is evident as conversion of S1P to (E)-2 hexadecenal and 
phosphoethanolamine can result in formation of phospholipids that have additional defined 
signalling functions in cells [14] and ceramide can be converted to C1P which has opposing 
actions to ceramide.  Therefore, the regulation of the sphingolipid rheostat in different cellular 
compartments is likely to provide finer tuning of cell biology than was previously considered.  
Bittman made a significant contribution to our understanding of sphingolipid signalling by 
developing reagents and chemical tools that allowed some of the functions of ceramide, C1P, 
sphingosine, S1P and hexadecenal to be identified.  
 
Ceramide: stress sensor and responder--In the late 1980s, the hydrolysis of sphingomyelin by 
sphingomyelinase was demonstrated to constitute a novel signal transduction pathway in 
mammalian cells.  The product, ceramide, can be acylated to sphingosine, which functions to 
inhibit protein kinase C (PKC) [15], or phosphorylated to C1P [16] by a calcium-dependent 
ceramide kinase, the function of which was unknown at the time.  Moreover, 1,25-
dihydroxyvitamin D3 was shown to activate sphingomyelinase to stimulate differentiation of 
HL60 cells [17, 18].  Sphingosine had also been demonstrated to promote the phosphorylation 
of the EGF receptor on Thr 669 in A431 human epidermoid carcinoma cells via a mechanism 
that was independent of PKC [19].   
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Diacylglycerol and ceramide were shown to have opposing cellular actions.  Thus, activation 
of PKC by diacylglycerol promotes cell survival whereas apoptosis is induced by ceramide 
[20, 21].  Bittman synthesised a cell-permeable ceramide, N-octanoyl sphingosine (C8-Cer) 
that was used LQFROODERUDWLRQZLWK.ROHVQLFN¶s group to induce a concentration- and time-
dependent increase in diacylglycerol levels in cells and which was associated with a reduction 
in phosphatidic acid levels [22]. C8-Cer was not metabolized to sphingomyelin and promoted 
PKC translocation from the cytosol to membrane, due to the increase in intracellular 
diacylglycerol.  The mechanism of action of ceramide was resolved by demonstration that it is 
a competitive (with diacylglycerol) inhibitor of diacylglycerol kinase, the enzyme that 
catalyses the conversion of diacylglycerol into phosphatidate [22].  Therefore, these studies 
identified that functional cross-talk between phospholipid- and ceramide-dependent signalling 
pathways exist in mammalian cells.  The significance of these findings contextualised prior 
studies, which had demonstrated that ceramide promotes apoptotic cell death in the human 
myeloid leukaemia cell lines HL-60 and U937 [21] and this is suppressed by diacylglycerol 
[23]. 
 
The role of ceramide in the induction of apoptotic death had become evident from attempts to 
decipher the signalling mechanisms activated by 1,25-dihydroxyvitamin D3 [17, 18] and which 
was significantly helped by use of ceramide analogues, such as C2-ceramide [20].  Others 
demonstrated that ceramide was also able to activate protein phosphatase 2A (PP2A) [24, 25].  
Activation of heterotrimeric PP2A was specific for ceramide because related sphingolipids had 
no effect.  Indeed, dihydro-C2-ceramide, which lacks the trans-double bond in the sphingoid 
base inhibited PP2A activity.  Later studies showed, for instance, that the ceramide-activated 
protein phosphatase is involved in deactivating the PKB/Akt pathway [26, 27], down-
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regulating c-Myc [25] and promoting dephosphorylation of retinoblastoma protein to induce 
growth arrest [28] thereby providing molecular detail to ceramide-dependent signalling and 
biological responses.  
 
Bittman made contributions in this area with studies investigating the effect of N-octanoyl-
sphingosine (C8-Cer) stereoisomers, N-octanoyl-DL-erythro-dihydrosphingosine (DL-e-
DHC8-Cer), and N-octyl-D-erythro-sphingosine (D-e-C8-Ceramine) on apoptosis in U937 
cells [29].  D- and L-threo stereoisomers were demonstrated to be more potent than the erythro 
analogues in inducing apoptosis.  D-e-C8-Cer, D-t-C8-Cer and D-e-C8-Ceramine induced the 
elevation of endogenous ceramide, but this did not account for their apoptotic effect.  In 
addition, okadaic acid (PP2A inhibitor) failed to protect U937 cells from apoptosis induced by 
D-e-C8-Cer.  There was also controversy at the time as to the significance of the 4,5-trans-
carbon-carbon double bond in short chain ceramides concerning cytotoxicity. These studies 
resolved that the absence of the 4,5-trans double bond in DHC8-Cer reduced cytotoxicity.  
 
Bittman also synthesised analogues of ceramide with a view to exploiting their potential anti-
cancer activity.  For instance, (2S,3R)-(4E,6E)-2-octanoylamidooctadecadiene-1,3-diol (4,6-
diene-Cer) was synthesised [30].  This analogue contains an additional trans double bond at 
C(6)-C(7) of the sphingoid backbone and was demonstrated to be more potent in inducing 
apoptosis than ceramide in TNFD-resistant and TNFD-sensitive MCF-7 cells.  4,6-diene-Cer 
caused a prolonged elevation of intracellular ceramide levels in MCF-7 cells and induced 
apoptosis as evidenced by the release of cytochrome c, loss of membrane asymmetry and 
reduced mitochondrial membrane potential. Bittman also synthesised an analogue of short 
chain ceramides with a disulfide linkage, N-(4',5'-dithiaheptanoyl)-D-erythro-ceramide) and in 
collaboration with Arthur, demonstrated that this compound induced significantly more 
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cytotoxicity than short chain ceramides in BT549, A549, and DU145 cancer cells [31]. The 
activity was associated with a reduction in cellular glutathione (GSH) level, which had been 
proposed some time before to be a critical step in neutral sphingomyelinase activation and 
subsequent ceramide-induced apoptosis [32].  Bittman and colleagues also demonstrated that 
the C(4)-C(5) trans-double bond has little influence on the ability of apoptosis regulatory 
proteins, Bax and Bcl-xL, to bind to the ceramide channels [33]. However, the stereochemistry 
of the head group and access to the amide group of ceramide is essential for Bax, but not Bcl-
xL binding. Bcl-xL was shown to also optimally bind long-chain apoptotic ceramides.  
 
Bittman synthesised many FTY720 analogues some of which targeted various key enzymes 
involved in sphingolipid metabolism such as ceramide synthases and sphingosine kinase. 
FTY720 modulates the immune response by preventing egress of T-lymphocytes from lymph 
nodes [34].  FTY720 (GilenyaTM) is licenced for oral treatment of relapsing multiple sclerosis 
and is a pro-drug, which is phosphorylated by sphingosine kinase 2 (SK2).  FTY720 phosphate 
is a functional antagonist of the S1P1 receptor, causing its proteasomal degradation and removal 
from T-lymphocytes [34].  Since T-lymphocytes use an S1P gradient to egress from lymph 
nodes, FTY720 is able to prevent this by creating S1P1 null T-lymphocytes that do not respond 
to the S1P gradient, thereby ablating their action on the central nervous system in multiple 
sclerosis.  However, it is clear that FTY720 can affect other targets in cells.  Indeed, Bittman 
was involved in two studies that demonstrated that FTY720 modulates de novo synthesis of 
ceramide.  In collaboration with Futerman and colleagues, FTY720 was shown to inhibit 
ceramide synthase activity in a non-competitive manner with acyl-CoA and an uncompetitive 
manner with sphinganine [35].  The inhibitory effect of FTY720 was dependent on acyl-CoA 
chain length.  Ceramide synthesis was inhibited at high (0.5-5 PM) but not low (< 200 nM) 
sphinganine concentrations in cells.  Ceramide, sphingomyelin, and hexosylceramides levels 
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were increased in response to FTY720, possibly a consequence of additional effects on, for 
instance, sphingosine kinase 1 (SK1).  These findings were highly informative in defining the 
complexity of the mechanism of action of FTY720.  FTY720 is known to induce apoptosis of, 
for instance, cancer cells, and therefore modulation of ceramide levels might underlie, in part, 
this mechanism of action.  In collaboration with Natarajan¶V JURXS, stable isotope pulse 
labelling of human pulmonary artery endothelial cells was used to establish that FTY720 
modulates de novo ceramide synthesis [36].  
 
Alpha-galactosylceramide (alphaGalCer) and its isosteric C-glycoside analogue activate 
natural killer T (NKT) cells [37].  Bittman synthesised a truncated non-isosteric C-alphaGalCer 
analogue that, in common with its isosteric C-glycoside analogue, is not enzymatically labile 
at the glycosidic linkage.  Instead the analogues have the anomeric carbon directly bonded to 
the C1 of the phytoceramide backbone. Comparison of the three ligands using human dendritic 
cells as the antigen-presenting cells and human NKT cells as the responding cells demonstrated 
that these lipids preferentially promote Th1-immune responses and might therefore serve as 
potent adjuvants in the immunotherapy of cancer and infectious diseases. 
 
Sphingomyelin--Structural activity relationships concerning specificity of sphingomyelinase 
were studied [38]. Four analogues of sphingomyelin were synthesized E\%LWWPDQ¶VODERUDWRU\
in which the C-3 hydroxyl group was replaced by a hydrogen atom (to produce a deoxy-
sphingomyelin analogue), or with O-methyl, O-ethyl or O-tetrahydropyranyl groups. The 
deoxy-sphingomyelin analogue failed to compete with a substrate of sphingomyelinase and 
was not hydrolysed by the enzyme, suggesting that the hydroxyl group is essential for activity.  
The size of the alkyl group on the ether moiety was also found to be important.  Thus, the 3-
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O-tetrahydropyranyl-sphingomyelin failed to compete with substrate of neutral pH-optimum 
sphingomyelinase. 
 
Ceramide 1-phosphate--Bittman in collaboration with Gomez-Muñoz and Brindley 
demonstrated that C2- and C8-Ceramide-1-phosphates (N-acetylsphingosine-1-phosphate and 
N-octanoylsphingosine-1-phosphate, respectively) stimulated DNA synthesis and promoted 
division of fibroblasts [39].  Recent studies by Gomez-Muñoz and Bittman demonstrated that 
C1P stimulates reactive oxygen species (ROS) formation in primary bone marrow-derived 
macrophages and that C1P induced ROS formation promotes mitogenesis of macrophages [40].  
This requires activation of NADPH oxidase, which is down-stream of C1P-dependent 
activation of cytosolic calcium-dependent phospholipase A2 and PKCD.  Bittman contributed 
to this study by synthesising BHNB (4-bromo-5-hydroxy-2-nitrobenzhydryl)-C1P (a 
photolabile caged-C1P analogue), which was critical to the study because it allowed 
demonstration that C1P elicits these effect via an intracellular action.  This was an important 
advance as it distinguished the actions from those in which C1P can elicit extracellular effects 
via a putative unidentified cell surface receptor. 
 
Sphingosine--Contributions to this area of research is evident by studies showing that sphingoid 
EDVHVV\QWKHVLVHGLQ%LWWPDQ¶VODEoratory induced apoptosis in HL-60 and U937 cells via a 
mechanism that did not involve their acylation to ceramides by ceramide synthases.  Thus, 
Fumonisin B1 (FB1, ceramide synthase inhibitor) failed to abrogate the effects of the sphingoid 
bases [41].  These sphingoid bases inhibited PKC and potentiated the lethal effects of ceramide, 
thereby providing evidence that PKC, which is inhibited by sphingoid bases, has a 
cytoprotective role in leukemic cells.  This was followed by studies using 
phenethylisothiocyanate derivatives of sphinganine and sphingosine (PEITC-Sa and PEITC-
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So) tKDWZHUHV\QWKHVLVHGLQ%LWWPDQ¶VODEoratory [42].  The PEITC-sphingoid base derivatives 
were shown to exhibit higher cytotoxicity (by PKC inhibition) than their natural counterparts 
and the clinically tested sphingoid base, safingol.  Such studies, highlighted the potential use 
of synthetic lipids as conventional PKC/novel PKC chemotherapeutic agents. 
 
%LWWPDQDOVRFROODERUDWHGZLWK+OD¶s group to identify novel intracellular targets of sphingosine 
[43].  Using affinity chromatography and proteomics, they identified acidic leucine-rich 
nuclear phosphoprotein-32A (ANP32A; an inhibitor of PP2A) as a direct binding target of 
sphingosine and N,N'-dimethylsphingosine (DMS). DMS relieved the ANP32A-mediated 
inhibition of PP2A and induced stimulation of the p38 MAPK pathway and expression of 
cyclooxygenase (COX)-2 in HUVEC cells. These studies therefore advanced the field by 
identifying signalling pathways in which sphingosine is involved.  The sphingosine mimetic, 
FTY720 was also known to activate PP2A, a tumour suppressor.  Indeed, certain 
myeloproliferative neoplasms are characterized by the expression of the Jak2(V617F) 
oncogene, which inactivates PP2A.  Bittman synthesised FTY720, which was used to reactivate 
the PP2A and reduce Jak2(V617F) activity and clonogenic potential [47]. Likewise, FTY720 
decreases leukemic allelic burden and splenomegaly and increases Jak2(V617F) leukemic mice 
survival.  The effects of FTY720 require a PP2A interacting protein SET K209. In contrast, 
FTY720-P, acting as a S1P1 receptor agonist, promotes Jak2-SET-mediated PP2A inhibition.  
These findings were important not least in defining the interplay between the S1P signalling 
pathway, SET2-PP2A and Jak2, but also in identifying novel strategies for eliminating the 
oncogenic drive in myeloproliferative neoplasm [44]. 
 
Previous studies had demonstrated that sphingosine and FTY720 could disrupt the proliferative 
signalling of the scaffold and adapter protein 14-3-3 [45] by enabling its protein kinase A 
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(PKA)-catalysed phosphorylation of Ser58 which destabilizes 14-3-3 dimerization.  Dimeric 
14-3-3 is functional, and the phosphorylation prevents the pro-survival action of 14-3-3 in cells.  
In a study published after %LWWPDQ¶V death, Woodcock and colleagues used FTY720 mimetics 
(quaternary ammonium analogues of FTY720) to stimulate phosphorylation of 14-3-3 at Ser58, 
which is deep in the interface of the dimer, resulting in mitochondrial-mediated apoptosis.  
Bittman laboratory synthesised RB-011 and RB-012, which are poor inhibitors of sphingosine 
kinase [46] and these were used to disrupt 14-3-3 dimers at low micromolar concentrations and 
to induce abrogation of Raf-ERK-1/2 and PI3K/Akt signalling in Jurkat cells [47].  RB-011 
and RB-012 were also shown to induce apoptosis of human A549 lung cancer cells and RB-
012 reduced xenograft growth of these tumours in mice. When mutant phosphorylation 
deficient 14-3-3 proteins are expressed in cells, they function in a dominant negative manner 
forming dimers with endogenous 14-3-3 that disrupts ERK-1/2 signalling.  The phenotype was 
recapitulated by RB-012.  These compounds were therefore used not only to demonstrate 
potential therapeutic utility in targeting 14-3-3 as an anti-cancer strategy, but also in delineating 
novel pathways by which sphingosine can regulate cell death. 
 
Sphingosine 1-phosphate--The first suggestion that S1P might function as a bioactive lipid 
came from studies showing that sphingosine mobilised calcium from intracellular stores 
mediated from a product of sphingosine and believed to be S1P [48].  Subsequent studies 
demonstrated that a number of effects attributed to sphingosine, were mediated by S1P 
including the stimulation of DNA synthesis of Swiss3T3 fibroblasts [49].  Others demonstrated 
that S1P inhibits cell motility and tumour invasiveness [50].  Additional studies characterised 
the enzymes involved in the metabolism of S1P including sphingosine kinase, S1P lyase and 
OLSLGSKRVSKDWHSKRVSKDWDVHV %\ WKHPLG¶V WKHUHZDV FRPSHOOLQJHYLGHQFH WKDW63
could also induce pertussis toxin-dependent cell signalling responses, such as ERK-1/2 
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activation that suggested some of the S1P responses were mediated by specific G protein-
coupled receptors (GPCR) [51, 52]; this was later confirmed by the identification of five S1P-
specific GPCR, now termed S1P1-5.  In addition, there were several studies that attempted to 
decipher and distinguish the bioactive functions of ceramide, sphingosine and S1P. Due to the 
nature of their inter-conversion, delineation of their individual roles was not a trivial exercise.  
Several studies lead to the concept of the sphingolipid rheostat.  This was deduced from 
assessment of the effect of ceramides, sphingosine and S1P on phospholipase D activity and 
mitogenesis in fibroblasts [53] and on ERK-1/2, JNK/SAPK, p70S6K and cAMP signalling in 
airway smooth muscle cells [54].  Later, S1P was shown to inhibit ceramide-induced cell death, 
which also blocked ceramide-induced stress activated signalling (JNK/SAPK) in U937 cells 
and Jurkat cells [55].  These studies provided evidence that elucidated different biological 
effectors of ceramide, sphingosine and S1P, thereby separating the function of these 
sphingolipids.    
 
%LWWPDQ¶VLQWHUHVWLQS1P VWDUWHGLQWKHPLG¶s when the controversy and debate concerning 
whether this lipid induced specific cell biological responses was at its height.  Spiegel and 
colleagues had shown that S1P and sphingosylphosphorylcholine (SPC) stimulate DNA 
binding activity of activator protein-1 (AP-1) in Swiss 3T3 fibroblasts [56]. The collaboration 
with Bittman demonstrated that the free 2-amino group and the 4E double bond of SPC and 
S1P were important for AP1 transactivation [57]. A reduction in sphingoid backbone chain 
length, substitution of the 3-hydroxyl group or saturation of the 4E bond significantly reduced 
the mitogenic/AP-1 transactivation induced by S1P, but not as significantly for SPC.  These 
early studies highlighted the power of structural-activity relationships in defining functionality 
to S1P over other sphingolipids, identified S1P as a bona fide bioactive lipid and suggested 
applications in wound healing and inhibition of metastasis. 
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Studies on sphingosine 1-phosphate receptors 
In addition to the regulation of sphingolipid signalling in cells mediated through changes in 
dynamic flux through the sphingolipid rheostat, it is now clear that S1P can exert biological 
actions through a variety of G-protein coupled receptors whose natural ligand is S1P.  The 
identification and cloning of five S1P receptors opened avenues of research in which Bittman 
could utilise his chemical synthetic expertise to expand our knowledge of the structural activity 
relationship of receptor function and the role of each S1P receptor type in cell biology. His first 
contribution in this area was the synthesis of two photoreactive analogues of S1P; [32P]-labelled 
(2S,3R)-14-O-(4'-benzoylphenyl)- and (2S,3R)-14-O-((4'-trifluoromethyldiazirinyl)phenyl)-
(4E)-tetradecenyl-2-amino-3-hydroxy-1-phosphate [58]. The S1P1 receptor bound the 
benzophenone-containing ligand, while no specific binding was found with the diazirine-
containing ligand.  In contrast both ligand bound to plasma carrier proteins (presumably 
albumin).  These studies revealed that different parts of the S1P pharmacophore of S1P interact 
with its receptor and plasma carrier proteins. 
 
Bittman also explored the activity of FTY720 and FTY720-phosphate in a number of biological 
systems.  For instance, the effect of S1P and FTY720-phosphate on constrictor responses were 
investigated in bladder smooth muscle (detrusorLQFROODERUDWLRQZLWK6SLHJHO¶VJURXS [59].  
S1P-induced a phasic and tonic contraction of detrusor muscle that was dependent S1P2.  The 
phasic response required phospholipase C (PLC).  FTY720-phosphate, an agonist for all S1P 
receptors except S1P2 induced a slow and sustained contraction, suggesting that this contraction 
phase was dependent on a receptor independent mechanism (possibly calcium Trp channel 
and/or voltage-operated calcium channels).  Detrusor tone is deregulated in overactive bladder 
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syndrome, suggesting that S1P signalling might represent a therapeutic target in this disease.  
Bittman and colleagues also achieved the first enantio-selective synthesis of chiral isosteric 
phosphonate analogues of FTY720 and demonstrated, LQFROODERUDWLRQZLWK7LJ\L¶VJURXS, that 
the (R)-FTY720-vinylphosphonate was a full agonist of S1P1 while the (S) enantiomer was a 
pan-antagonist of S1P1-5 receptors [60, 61].  Both enantiomers inhibited autotaxin, induced 
transient peripheral lymphopenia and produced an anti-apoptotic effect in camptothecin-treated 
IEC-6 intestinal epithelial cells. At concentrations above 1 PM, (S)-FTY720 vinylphosphonate 
no longer exhibited an anti-apoptotic effect.  This was consistent with other studies involving 
collaboration with the Pyne group which demonstrated that (S)-FTY720 vinylphosphonate (> 
1 PM) inhibited sphingosine kinase 1 (SK1) activity and promoted its proteasomal degradation 
and this was associated with an apoptotic effect in prostate and breast cancer cells [62].  Such 
studies highlighted the complexity of the pharmacological intervention of the S1P signalling 
pathway. 
 
The biological action of FTY720-phosphate at S1P1 receptors in T-lymphocytes was initially 
considered to underlie the major effect of this compound in alleviating symptoms of multiple 
sclerosis.  However, there is now a general agreement that FTY720-phosphate can also exert 
direct effects on the central nervous system.  Indeed, there was demonstration of a direct 
protective effect of FTY720-phosphate on oligodendrocyte progenitors that maintain 
myelination of neurons in the brain [63].  Treatment of these cells with FTY720 causes 
activation of ERK-1/2 and Akt, and protection from apoptosis. However, FTY720 also arrested 
oligodendrocyte differentiation counteracted by neurotrophin-3, which not only enhanced the 
survival of oligodendrocyte progenitors induced by FTY720 but also stimulated their 
maturation.  These studies raised the possibility that multiple sclerosis therapies with FTY720 
should include the use of differentiation-enhancing factors such as neurotrophin-3.   
 15 
 
 
Bittman in collaboration with Garcia, Dudek and Natarajan explored the potential effect of 
FTY720 analogues on vascular endothelial cell barrier integrity in terms of inflammatory 
diseases such as acute lung injury.  It had been demonstrated that S1P and FTY720 exhibit 
potent barrier-HQKDQFLQJ DFWLYLW\  %LWWPDQ¶V ODERUDWRU\ synthesised a number of FTY720 
analogues that were used in collaboration with Dudek and colleagues to assess effect on 
endothelial barrier integrity [64].  They demonstrated that the (R)- and (S)-enantiomers of 
FTY720-phosphonate induced a sustained endothelial cell barrier enhancement that was 
effective in a lower concentration range and with an earlier onset than either S1P or FTY720. 
Indeed, the (S)-FTY720-phosphonate reduced alveolar and vascular permeability in a 
lipopolysaccharide-stimulated murine model of ALI without induction of lymphopenia.  These 
findings suggest therapeutic utility for FTY720 analogues in reducing pulmonary vascular 
leakage and inflammation and which might have implication for future treatments of acute lung 
injury.  Indeed, these studies were extended in collaboration with Garcia to demonstrate that 
radiation-induced lung injury, which is a common toxicity in patients administered thoracic 
radiotherapy, is reduced by (S)-FTY720-phosphonate, along with decreased radiation-induced 
gene dysregulation [65].  These results were supported by findings which demonstrated that 
mice with deletion of SK1 (SK1-/-) or with reduced expression of certain S1P receptors (S1P1
+/-
, S1P2
-/-, and S1P3
-/-) exhibited radiation-induced lung injury susceptibility. (S)-FTY720-
phosphonate was also assessed in a bleomycin-induced lung injury model and was shown to 
reduce lung leak and inflammation, while maintaining S1P1 receptor expression.  Indeed, (S)-
FTY720-SKRVSKRQDWH GRHV QRW LQGXFH ȕ-arrestin recruitment and does not promote S1P1 
ubiquitination and proteasomal degradation.  This contrasted with FTY720, which did not 
protect against bleomycin-induced acute lung injury in mice and significantly down-regulated 
S1P1 receptor expression.  The significant advance here was the identification of a compound 
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that promotes barrier integrity but lacks the potential barrier disrupting effect of down-
regulating S1P1 [66].  
 
Tigyi and Bittman were also involved in a collaboration to map the binding site of FTY720-
phosphate in S1P receptors [67].  To achieve this they exploited the fact that FTY720-
phosphate binds to the S1P1 receptor but not the S1P2 receptor. A constructed S1P2 chimera 
with S1P1 sequence from the N terminus to transmembrane domain 2 was activated by 
FTY720-phosphate and exhibited an S1P1-like activation. Twelve residues in this inserted 
domain, distributed in four motifs (a-d), differ between S1P1 and S1P2. Insertion of RPMYY 
in motif b alone or simultaneous swapping of five other residues in motifs c and d from S1P1 
into S1P2 introduced responsiveness to FTY720-phosphate.   Thus, the use of FTY720-
phosphate enabled insight into specific receptor-ligand interactions. 
 
Studies on sphingosine kinases  
The modulation of the sphingolipid rheostat to shift the balance to formation of apoptotic 
ceramide provides a potential means to abrogate hyper-proliferative diseases such as vascular 
remodelling in pulmonary hypertension and both solid and haematological cancers.  
Sphingosine kinase (SK) is a logical target for therapeutic intervention since inhibition of this 
enzyme functions to prevent conversion of sphingosine into S1P, with concomitant back 
conversion of sphingosine into apoptotic ceramide.  With this rationale, a collaboration was 
established between Bittman and the Pyne group to synthesise and test sphingoid base and 
FTY720 analogue inhibitors of SK1 and SK2.  The demonstration that FTY720 inhibits SK1 
activity [62] provided a strong rationale for development of FTY720 analogues as SK 
inhibitors.  Moreover, (S)-FTY720 vinylphosphonate was shown to be an allosteric inhibitor 
of SK1 activity [68, 69] and function to stabilise a conformation of SK1 that enhances auto-
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inhibition of the catalytic site.  In addition, two new FTY720 analogues (a conjugate of 
sphingosine with a fluorophore and (S)-FTY720 regioisomer) stimulated SK1 activity, 
suggesting relief of the auto-inhibition of SK1 activity [68]. These studies were extended by 
demonstration that replacement of the amino group in (S)-FTY720 vinylphosphonate with an 
azido group converted the (S)-FTY720 vinylphosphonate from an allosteric inhibitor to an 
allosteric activator of SK1 at low PM concentrations [70].  (S)-FTY720 vinylphosphonate also 
induced the proteasomal degradation of SK1 in androgen-independent prostate cancer cells and 
promoted the apoptosis of these cells, which are highly resistant to chemotherapeutic agents 
[68]. 
 
%LWWPDQ¶V ODEoratory also undertook the stereospecific synthesis of an analogue of FTY720 
called (R)-FTY720-OMe (ROMe), which was demonstrated, in collaboration with the Pyne 
group, to be a competitive inhibitor of SK2. (S)-FTY720-OMe failed to inhibit SK1 activity, 
thereby demonstrating stereospecific inhibition of SK2 [71]. Prolonged treatment of HEK293 
cells with ROMe also induced a reduction in SK2 expression, inhibited DNA synthesis and 
prevented S1P-stimulated rearrangement of actin in MCF-7 breast cancer cells, indicative of 
an application to prevent metastasis.  ROMe also induced autophagic death of T-cell acute 
lymphoblastic leukemia cells [72] and promoted growth arrest in MDA-MB-231 breast cancer 
cells [73].  The latter involves the accumulation of the S1P2 receptor in the nucleus of cells 
treated with ROMe; a process which is recapitulated by knockdown of SK2 with siRNA [73]. 
 
Bittman¶V laboratory also synthesized inhibitors that were selective for SK1 and SK2. For 
example, the thiourea adduct of sphinganine (F-02) was selective for SK2 whereas the 1-
deoxysphinganines 55-21 and 77-7 were selective for SK1. (2S,3R)-1-deoxysphinganine (55-
21) induced the proteasomal degradation of SK1 in human pulmonary arterial smooth muscle 
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cells and inhibited DNA synthesis, while the more potent SK1 inhibitors PF-543 and 
VPC96091 failed to inhibit DNA synthesis [74]. These findings indicated that moderate 
potency inhibitors such as 55-21 are likely to have utility.  There was also the design, synthesis, 
and evaluation of the potency of new isoform-selective inhibitors of SK1 such as 1-(4-
octylphenethyl)piperidin-4-ol) (RB-005) [46, 75].  Structural activity relationship analysis was 
performed in which the lipophilic tail, polar head group, and linker region were modified.  
Using modelling studies with the recently published crystal structure of SK1, the basis for the 
key residues targeted by this profiled series was achieved along with identification of 
determinants that provide a rationale for the development of inhibitors with better selectivity 
for SK2 over SK1 [75]. 
 
Studies on sphingosine 1-phosphate lyase  
&ROODERUDWLRQEHWZHHQ%LWWPDQDQG6DED¶VJURXSLGHQWLILHGWHPSRUDODQGVSDWLDODFFXPXODWLRQ
of delta(4,6)-sphingadienes in Sply Drosophilia mutants that were linked with muscle 
degeneration [76].  Further work established that dietary sphingadienes induce colon cancer 
cell apoptosis and reduce intestinal tumourigenesis. This is achieved by inhibition of the 
translocation and activation of Akt to the plasma-membrane (without affecting PI3K) and 
subsequent stimulation of 4-EBP-1 phosphorylation thereby preventing proteins synthesis.  
Over-expression of constitutively activated Akt reduced sphingadiene-induced cell death, 
autophagy and apoptosis [77].  Byun and Bittman [78] then published the synthesis of 4,6- and 
4,8-sphingadienes on a scale of gram quantities.  The sphingadienes were also shown to reduce 
the OHYHOVRIȕ-catenin and Wnt targets such as c-Myc and cyclin D1 in Apc(Min/+) mouse 
intestinal tissues [79]. These effects are mediated vLDUHGXFHG*6.ȕOHYHOVDQGDUH ablated 
by over-expression of constitutively active Akt.  Moreover, combined treatment with 
sphingadienes and rapamycin decreased polyps in Apc(Min/+) mice.  The study also 
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demonstrated that sphingadienes inhibit Wnt signalling through a PP2A$NW*6.ȕ-
dependent mechanism that promotes anti-cancer activity.  More recent findings have 
demonstrated that dietary sphingadienes induce the up-regulation of S1P lyase expression and 
this reduces S1P levels and abrogates colon carcinogenesis.  The mechanism involves a 
sphingadiene-induced reduction in phosphorylated STAT3 levels and pro-inflammatory 
mediator production, such as TNFDand the interleukins, IL-6, IL-21 and IL-23 [80].   The work 
elegantly demonstrated that sphingodienes prevent tumourigenesis driven by STAT3 activated 
miRNAs that suppress anti-oncogenes. 
 
The collaboration between Saba and Bittman also explored whether trans-2-hexadecenal 
(produced upon the degradation of S1P by S1P lyase) has signalling functions in cells [81].  
The findings demonstrated that trans-2-hexadecenal induces cytoskeletal reorganization and 
an oxidative stress-dependent activation of JNK-mediated apoptosis.  This was evidenced by 
cytochrome c release, Bax activation, Bid cleavage and increased translocation of Bim into 
mitochondria.  In addition, Saba and Bittman showed that trans-2-hexadecenal reacts with 
deoxyguanosine and DNA to produce the diastereomeric cyclic 1,N(2)-deoxyguanosine 
adducts 3-(2-deoxy-ȕ-d-erythro-pentofuranosyl)-5,6,7,8-tetrahydro-8R-hydroxy-6R-
tridecylpyrimido[1,2-a]purine-10(3H)one and 3-(2-deoxy-ȕ-d-erythro-pentofuranosyl)-
5,6,7,8-tetrahydro-8S-hydroxy-6S-tridecylpyrimido[1,2-a]purine-10(3H)one with potentially 
mutagenic consequences [82]. 
 
Lysophosphatidic acid 
7KHELRORJLFDODFWLYLW\RI/3$ZDVILUVWLGHQWLILHGLQWKHODWH¶VZLWKWKHGHPRQVWUDWLRQ
that LPA can induce pressor responses [83], platelet aggregation [84] and neutrophil 
chemotaxis [85].  In addition, LPA was shown to markedly inhibit synaptic membrane 
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(Na+/K+)-ATPase activity in rat brain suggesting a role in depolarization and/or increase in 
intracellular calcium concentrations [86],QWKHHDUO\¶V/3$ZDVLGHQWLILHGDVDPLWRJHQ
that acted through a pertussis sensitive G-protein coupled receptor(s) and p21Ras in fibroblasts 
[87-89].  Tigyi et al. [90] demonstrated that LPA bound to serum albumin activated membrane 
currents in oocytes and induced neurite retraction in PC12 cells.  Numerous studies confirmed 
LPA to be a bioactive lipid and there has been extensive characterization of the receptors that 
mediate its action.  There are multiple species of LPA that account for its pleiotropic actions, 
including both mitogenic and anti-mitogenic effects in mammalian cellular systems [91].  
Different molecular species of LPA are found in biological fluids as saturated, and mono and 
poly-unsaturated variants of sn-1 or sn-2 regioisomers. The majority of LPA species in serum 
are unsaturated and these have higher potency at LPA receptors and intracellular targets, such 
as the peroxisome proliferator-activated receptor J [92].  Phospholipase A1 enzymes catalyse 
formation of unsaturated sn-2 LPA.  Cyclic phosphatidic acid (1-acyl-sn-2,3 cyclic phosphate) 
a naturally occurring analogue of LPA from the slime mould Physarum polycephalum to 
human blood [93, 94], alkyl-ether [95, 96] and alkenyl-ether analogues [97] of LPA have also 
been identified and are weak agonists of LPA-specific GPCR [98, 99].  In contrast, LPA5 
exhibits preference for 1-O-alkyl glycerophosphate compared with acyl analogues with the 
same chain length.  LPA binds to two classes of GPCR, namely the EDG family cluster (LPA1-
3) and the P2Y cluster (LPA4,5).  Additional members of the P2Y class include P2Y5 (LPA6), 
and potentially GPR35. The related GPCRs [100-102] and P2Y10 [103], in spite of initial 
claims of being activated by LPA, are no longer classified as LPA receptors.  LPS1/GPR34, 
LPS2/P2Y10 and LPS3/GPR174 are now established as lysophosphatidylserine receptors [104, 
105] 
 
 21 
 
Bittman extensively synthesised chemical tools to interrogate the structural functional aspects 
of LPA receptors.  His work also involved development of LPA agonists and antagonists that 
facilitated understanding of the pharmacology of ligands acting at LPA receptors.  In 
collaboration with Tigyi, N-palmitoyl-serine phosphate and N-palmitoyl-tyrosine phosphate 
were synthesized and shown to inhibit LPA-stimulated Cl- currents with nM potency in 
oocytes, thus rendering them as potential antagonists [106, 107].  The D- and L-stereoisomers 
were equally effective, consistent with the finding that both enantiomers of LPA bind to LPA 
receptors.  Both of these LPA antagonists lacked activity when microinjected into the oocyte 
and were not effective against acetylcholine, serotonin, and glutamate receptors that had been 
over-expressed in the oocyte.  In this 1996 publication that preceded the molecular cloning of 
the first LPA GPCR, the differential sensitivity to N-palmitoyl-serine and N-palmitoyl-tyrosine 
phosphates provided pharmacological evidence for multiple LPA receptor subtypes, which 
were named low- and high-affinity LPA receptors.  However, it took 13 years before N-
palmitoyl-serine phosphate was finally re-examined in cells transfected with individual LPA 
receptors to find that LPA1 was inhibited by this compound with an IC50= 3.45 µM whereas it 
was a weak agonist of LPA2 (GPR92) [108].  Interestingly, when platelets are pre-incubated 
with N-palmitoyl-serine phosphate prior to LPA exposure, their response is fully blocked [109, 
110].  Platelet activation is mediated by LPA5 [111].  The question arises as to why N-
palmitoyl-serine phosphate is inhibitory to this response?  One potential explanation lies in the 
pre-incubation of platelets used in the study where prolonged N-palmitoyl-serine phosphate 
exposure prior to LPA desensitizes LPA5 in the platelet.  Clearly, these acylated amino acid 
analogues represent a promising scaffold for lead development and deserve more investigation 
to develop new receptor-specific probes. 
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The pharmacological characterisation of LPA receptors was further advanced by the synthesis 
and characterisation of the LPA analogues, 1-O-hexadecyl-sn-glycero-3-phosphate (1-C16-
GP) and 3-O-hexadecyl-sn-glycero-1-phosphate (3-C16-GP).  These were shown to induce 
calcium mobilisation in RH7777 cells over-expressing either LPA1 or LPA2 or LPA3 indicating 
a lack of stereo-specificity in their action [112].  The enantiomers also induced Cl- transients 
in oocytes, which express LPA1 and PSP24 and heterologous desensitisation was evident in 
NIH3T3 cells (which express LPA1 and LPA2) stimulated with oleoyl-LPA and 1-C16-GP or 
3-C16-GP.  These findings indicated that these ligands bind to the same LPA receptors.  
Finally, both enantiomers were dephosphorylated by the lipid phosphate phosphatase, LPP1.  
This study importantly contributed to the notion that LPA binds to LPA receptor in a non-
stereospecific manner, while other unnatural analogues, such as N-acyl-serine phosphate and 
N-acyl-ethanolamine phosphate (which contain a serine and an ethanolamine backbone, 
respectively, in place of glycerol) bind to LPA receptors in a stereospecific manner.  There are 
also subtle differences in the binding of these ligands to different LPA receptor sub-types.  This 
provided a strong rationale and belief that it is possible to develop sub-type specific antagonists 
RI/3$UHFHSWRUVWKDWPLJKWH[KLELWWKHUDSHXWLFYDOXH%LWWPDQ¶VFRPSRXQGZLWKWKHJO\FHURO
backbone replaced with amino acid analogues had a profound impact on the development of 
LPA GPCR probes.  The realization that the glycerol backbone was not required for the ligand 
to activate or inhibit the receptors has fuelled the synthesis of fatty alcohol phosphates that 
completely lack the glycerol moiety yet depend on their hydrocarbon chain-length [113-115]. 
One of these analogues, octadecyl thiophosphate is an effective radioprotective agent that 
mitigates the acute radiation syndrome in mice and non-human primates via activation of the 
LPA2 receptor [114, 116, 117]. 
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The collaboration with Tigyi also lead to the finding that LPA is formed during mild oxidation 
of LDL leading to the stimulation of platelet activation and endothelial stress-fibre formation 
[110].  These effects were blocked by N-palmitoyl-tyrosine phosphate that had been 
synthesised and characterised in earlier work.  The significance of these findings was the 
identification of LPA in LDL where it is enriched in the lipid core and which is highly 
atherothrombogenic.  The effects on cardiovascular pathology were followed by studies on 
LPA targets distinct from the LPA GPCR.  The basis of these studies was that products formed 
during mild oxidation of LDL induce neointimal formation in the coronary artery; this is an 
important feature of the pathology of atherosclerosis. Bittman and Tigyi demonstrated that 
ethyl or acyl analogues of LPA also induce neointima formation.  These effects were blocked 
by an antagonist (GW9662) of the peroxisome proliferator-activated receptor gamma (PPARJ 
and mimicked by agonists of PPARJ (e.g. rosiglitizone).  This contrasted with a lack of effect 
of the PPARD agonist, stearoyl-oxovaleryl phosphatidylcholine, which failed to induce neo-
intimal formation [118]. Moreover, extensive structural activity relationship analysis placed 
the effects of the LPA analogues with PPARJ rather than with LPA GPCR and highlighted a 
role in programming de-differentiation of vascular smooth muscle cells, an essential step in 
allowing these cells to enter the cell-cycle.  These seminal findings identified LPA as a natural 
ligand for the transcription factor, PPARJ and underscored the importance of this biological 
interaction by demonstrating an important role of LPA in the pathophysiology of coronary 
atherosclerosis.  This work was followed by demonstration that a naturally occurring ether 
analogue of LPA, 1-O-octadecenyl-2-hydroxy-sn-glycero-3-phosphate (AGP), is a potent 
partial agonist of PPARJ>119]AGP, which binds to PPARJ with a Kd = 60 nM, was 
demonstrated to displace 40% of the bound rosiglitizone from PPARJ and activated a PPARJ 
reporter gene expression by ~ 40% of that induced by rosiglitizone.  These findings categorised 
AGP as partial agonist of PPARJ. A key piece of evidence in support of the role of PPARJ in 
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neointimal growth came from the stereo-selective activation of the nuclear receptor by AGP.  
Bittman synthesized the 3-O-octadecenyl-2-hydroxy-sn-glycero-1-phosphate stereoisomer of 
AGP that failed to activate PPARJ unlike the naturally occurring AGP isomer [118].  This type 
of stereochemical selectivity distinguishes LPA GPCR from PPARJ%LWWPDQ¶VV\QWKHVLVRI
the LPA stereoisomeric compounds has been a prerequisite to delineating this essential 
difference between the two types of LPA targets. Molecular modelling of the ligands based on 
the PPARJ crystal structure suggested that AGP and rosiglitazone occupy partially overlapping 
positions but use different hydrogen bonding and ion pairing interactions. Site-directed 
mutagenesis demonstrated that H323 and H449 in PPARJ are essential for binding 
rosiglitizone, while R228 is essential for binding AGP.   The different modes of binding provide 
a molecular explanation for the full and partial agonism of rosiglitizone and AGP respectively.  
Information from such studies could conceivably be used to produce LPA analogues with full 
agonism properties and therefore of high therapeutic value in the treatment of atherosclerosis.   
 
%LWWPDQ¶VLQWHUHVWLQ/3$DOVRH[WHQGHGWRWhe development of chemical reagents used to assess 
autotaxin (ATX) activity.  ATX is a lysophospholipase D which catalyses the formation of 
LPA from lysophosphatidylcholine and has a role in cancer invasion, metastasis, tumour 
progression, neuropathic pain, fibrotic disease, cholestatic pruritus, lymphocyte homing and 
thrombotic diseases.  Bittman and colleagues synthesised a lysophosphatidylcholine-like 
fluorogenic substrate ADMAN-LPC [120] ZKLFK ZDV XVHG E\ 7LJ\L¶V JURXS WR VFUHHQ D
compound library, in order to find novel inhibitors of ATX [121]. Three compounds were 
identified, two of which (918013, (2,4-dichloro-N-(3-fluorophenyl)-5-(4-morpholinylsulfonyl) 
benzamide) and 931126, (4-oxo-4-{2-[(5-phenoxy-1H-indol-2-yl)carbonyl]hydrazino}-N-(4-
phenylbutan-2-yl)butanamide) were competitive inhibitors of ATX activity whereas another 
(966791, N-(2,6-dimethylphenyl)-2-[N-(2-furylmethyl)(4-(1,2,3,4-
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tetraazolyl)phenyl)carbonylamino]-2-(4-hydroxy-3 methoxyphenyl) acetamide) which was a 
competitive inhibitor of an alternative lyosphospholipase D fluorogenic substrate FS-3 and the 
phosphodiesterase substrate p-nitrophenyl thymidine 5'-monophosphate. Computational 
docking and mutagenesis demonstrated that the two competitive and selective ATX activity 
inhibitors target the hydrophobic pocket and block accessibility of the substrate to the active 
site of ATX. The compounds also exhibited biological activity in blocking the invasion of 
A2058 human melanoma cells and B16-F10 murine melanoma cells colonisation of the lung 
in C57BL/6 mice. The lasting legacy of these studies might be the longer term development of 
novel therapeutics targeting ATX in cancer metastasis. 
 
Ether linked lipids 
Bittman had a long lasting interest in the chemical synthesis and biology of ether linked lipids, 
and developed several productive collaborations which brought to the attention of the scientific 
community important applications for this class of lipids, particular as anti-cancer agents.  
%LWWPDQ¶V JURXS V\QWKHVLVHG ether-linked glycero-alpha- and beta-D-glucopyranosides and 
glycero-1-thio-alpha- and beta-D-glucopyranosides. In collaboration with Salari and 
colleagues, alpha-D-thioglucopyranoside [1-O-hexadecyl-2-O-methyl-3-S-(alpha-D-1'- 
thioglucopyranosyl-sn-glycerol)] was reported to be cytotoxic against cancer cells and lacked 
platelet aggregation activity [122].  3-S-(alpha-thioglycopyranosyl)-sn- glycerols bearing a 
long-chain O-alkyl group at the sn-1 position and a methoxy group at the sn-2 position of 
glycerol were therefore identified as anti-neoplastic agents with low risk of inducing 
thrombosis.  Bittman also synthesised the ether linked lipid, 1-O-hexadecyl-2-O-methyl-sn-
glycero-3-phosphocholine (ET16-OCH3-GPC) and demonstrated its ability to inhibit DNA 
synthesis of HL60 cells [123].  A non-hydrolysable analogue of ET16-OCH3-GPC was active, 
thereby suggesting that biological activity was attributable to ET16-OCH3-GPC rather than a 
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bio-transformed activity [123]. The ether-linked lipids were shown to compete with 
diacylglycerol/phosphatidylserine for binding sites on PKC, but this was not linked with 
cytotoxicity [124].  These workers also demonstrated that ET16-OCH3-GPC was not a platelet 
activating factor receptor modulator [125].  Thus, comparison with platelet activating factor 
agonists demonstrated opposing rank order potency for platelet aggregation activity versus 
cytotoxicity against WEHI-3B leukemic cells.  
 
In collaboration with Arthur, the anti-proliferative effect of ET18-OCH3 was demonstrated to 
involve blockade of Raf-1 association with Ras at the plasma-membrane resulting in ablation 
of the down-stream activation of the ERK pathway [126, 127].  ET-18-OCH3 was also shown 
to inhibit the phosphorylation and activation of p70 S6 kinase in MCF-7 Cells [128].  
Subsequently, Bittman synthesised enantiomeric unsaturated phosphonocholine analogues of 
ET-16-OCH3 which displayed differential cytotoxicity towards two neuroblastoma cell lines, 
SK-N-SH and SK-N-MC [129].  This was the first report of enanatioselectivity of AELs on 
antiproliferative activity and cytotoxicity. The differential cytotoxic effects of the enantiomers 
were demonstrated to be due to the differential activation of the JNK signalling pathway in the 
cells [129].   
 
Bittman with Arthur reported the synthesis of a GAEL, 1-O-hexadecyl-2-O-methyl-3-O-(2'-
amino-2'-deoxy-beta-D-glucopyranosyl)-sn-glycerol (Gln) that had comparable or better 
cytotoxic effects against human epithelial cancer cell lines than ET-18-OCH3 [130].  They 
demonstrated the mechanism by which glycosylated anti-tumour ether lipids (GAELs) exhibit 
anti-cancer activity. Gln activates autophagy but does not kill cells by this mechanism or 
through apoptosis [131].  Later studies demonstrated that Gln neutralises lysosomal pH, 
increases autolysosome formation and promotes lysosomal membrane permeabilization with 
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the release of hydrolases into the cytoplasm, which then promote cell death [132].  Gln was 
also shown to diffuse across cell membranes into lysosomes, where protonation of the amine 
results in the formation of vacuoles [133].  Such studies highlighted the distinct killing 
mechanisms perpetrated by phospholipids and sphingolipids.   
 
The collaboration also demonstrated that ether-linked glucosyl diglycerides represent a distinct 
group of anti-tumour ether lipids from alkylphosphocholines and alkyllysophospholipids. The 
studies demonstrated that 4-O-hexadecyl-3(S)-O-methoxybutanephosphonate was more active 
than 1-O-octadecyl-2-O-methyl-glycero-3-phosphocholine in epithelial cancer cell lines.  
Since LPA was non-mitogenic in all the cell lines except the neuroblastoma line SK-N-SH, it 
is unlikely that the inhibition of cell proliferation by 4-O-hexadecyl-3(S)-O-
methoxybutanephosphonate is due to antagonism of the action of LPA at its GPCRs [130].   
 
These studies and others described here clearly defined different classes of ether lipids as 
having unique biological activities that could be distinguished from other phospholipids.  This 
was further extended to consider glycosylated analogues of ET-18-OCH3.  Stereospecific 
glycosylation was achieved with analogues differing from ET-18-OCH3 by the replacement of 
the sn-3-phosphocholine residue with either beta- and alpha-2-deoxy-D-arabino-
hexopyranosyl, alpha-D-mannopyranosyl or 2-O-methyl-beta-D-glucopyranosyl, and 2-O-
methyl-alpha-D-mannopyranosyl. The value of these studies was exemplified by the finding 
that 1-O-Hexadecyl-2-O-methyl-3-O-(2'-deoxy-beta-D-arabino-hexopyranosyl)-sn-glycerol 
was more effective than ET-18-OCH3 in inhibiting the growth of cancer cells [134].   
 
Bittman and Arthur also studied the effects of D-myo-inositol 4-(hexadecyloxy)-3(S)-
methoxybutanephosphonate (C4-PI), an isosteric phosphonate analogue of 
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phosphatidylinositol.  C4-PI was shown to inhibit PI-phospholipase C-beta (PLC-E) while 
activating PI-PLCJ and PI-PLCG at low concentrations and inhibiting these enzymes at higher 
concentrations.  C4-PI had little effect on PI4-kinase activity and blocked the proliferation of 
MCF-7 and MDA-MB-468 cell lines [135]. 
 
Synopsis 
In the present review we compiled a partial account of the contributions made by Robert 
Bittman to select areas of lipid research. His legacy will live on not only in over 340 
publications he authored but also in the concepts that evolved from research enabled by the 
compounds he made available to lipid researchers. The compounds he synthesized not only 
had a profound impact on the pursuit of the biological function of several important lipid 
mediators but also accelerated research toward their therapeutic exploitation.  
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